3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
27
Neoplasms
8
Lung Neoplasms
6
Neoplasms by Site
3
Neoplasm Metastasis
3
Lymphoma, Large-Cell, Anaplastic
3
Hematologic Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Interventions
Carboplatin
15
Pemetrexed
8
Paclitaxel
6
pembrolizumab
5
osimertinib
4
atezolizumab
4
Gemcitabine
4
Erlotinib Hydrochloride
4
entinostat
3
durvalumab
3
Cisplatin
3
selpercatinib
2
pralsetinib
2
camrelizumab
2
apatinib
2
Vinorelbine
2
Radiosurgery
2
Nivolumab
2
Injections
2
Gefitinib
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
toripalimab
1
sotorasib
1
sintilimab
1
repotrectinib
1
pegylated granulocyte colony-stimulating factor
1
patritumab
1
necitumumab
1
napabucasin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thoracic Neoplasms
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts